Liu Baoxin, Li Yong, Luo Jiachen, Dai Liming, Zhao Jinlong, Li Hongqiang, Jie Qiqiang, Wang Dongzhi, Huang Xin, Wei Yidong
Department of Cardiology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, China.
Department of Periodontics, College of Dentistry, University of Illinois at Chicago, Chicago, IL 60612, United States.
Thromb Res. 2016 Dec;148:25-31. doi: 10.1016/j.thromres.2016.10.010. Epub 2016 Oct 13.
To examine plasma protein Z (PZ) levels in acute myocardial infarction (AMI) and chronic coronary atherosclerosis disease (CCAD) patients without history of AMI and explore its potential clinical significance.
Plasma PZ concentrations were measured in 90 AMI patients (Group A), 87 CCAD patients without AMI history who remained free of major clinical events at least one year (Group B), and 88 clinically healthy controls (Group C).
PZ was found to be significantly lower (P<0.001) in Group A (1508.5±486.2ng/mL) compared with Group B (1823.0±607.8ng/mL) and C (2001.7±733.0ng/mL) and in Group A+B compared with Group C (Group A+B 1663.1±570.0 ng/mL, P<0.001). No statistically significant difference was reached between Group B and C (P=0.081). PZ level was significantly correlated with concentration of creatine kinase MB, high sensitive-cardiac troponin T, high sensitive C reactive protein, D-dimer and coagulation factor II and may be a useful predictor for AMI (OR: 1.38, 95% CI: 1.13-1.77, P=0.03). Subgroup analysis showed PZ concentration below the lowest tertile (<1398ng/mL) had a significantly increased risk for AMI and CCAD (OR: 3.39; 95% CI: 1.12-10.31; P=0.03 and OR: 7.39; 95% CI: 2.62-20.79; P<0.001 respectively).
PZ deficiency is found in AMI patients and could potentially reflect the myocardium injury, local coagulation activation and inflammation response during the acute phase of coronary atherosclerosis disease.
检测急性心肌梗死(AMI)患者及无AMI病史的慢性冠状动脉粥样硬化疾病(CCAD)患者的血浆蛋白Z(PZ)水平,并探讨其潜在的临床意义。
检测90例AMI患者(A组)、87例无AMI病史且至少1年无重大临床事件的CCAD患者(B组)和88例健康对照者(C组)的血浆PZ浓度。
A组(1508.5±486.2ng/mL)的PZ水平显著低于B组(1823.0±607.8ng/mL)和C组(2001.7±733.0ng/mL)(P<0.001),A组+B组的PZ水平也显著低于C组(A组+B组1663.1±570.0ng/mL,P<0.001)。B组和C组之间无统计学显著差异(P=0.081)。PZ水平与肌酸激酶MB、高敏心肌肌钙蛋白T、高敏C反应蛋白、D-二聚体及凝血因子Ⅱ浓度显著相关,可能是AMI的有效预测指标(OR:1.38,95%CI:1.13-1.77,P=0.03)。亚组分析显示,PZ浓度低于最低三分位数(<1398ng/mL)的患者发生AMI和CCAD的风险显著增加(OR分别为:3.39;95%CI:1.12-10.31;P=0.03和OR:7.39;CI:2.62-20.79;P<0.001)。
AMI患者存在PZ缺乏,这可能反映了冠状动脉粥样硬化疾病急性期的心肌损伤、局部凝血激活及炎症反应。